TRAX (First Tracks Biotherapeutics) Other Financing: $0.00 Mil (TTM As of Dec. 2024)


TRAX First Tracks Biotherapeutics Inc TRAX
12 GF Score
Price $36.24
! 3 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics Other Financing?

First Tracks Biotherapeutics TRAX +11.85% 12 Other Financing is $0.00 Mil as of Dec. 2024. GuruFocus rates TRAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

First Tracks Biotherapeutics's Other Financing for the six months ended in Dec. 2024 was $0.00 Mil.

First Tracks Biotherapeutics's Other Financing for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

First Tracks Biotherapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics Other Financing Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
Other Financing
0.00 0.00

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
Other Financing 0.00 0.00
TRAX
12GF Score
First Tracks Biotherapeutics Inc TRAX
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Other Financing for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $0.00 Mil mean?
First Tracks Biotherapeutics (TRAX) has a Other Financing of $0.00 Mil as of Dec. 2024. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for First Tracks Biotherapeutics and its competitors.
Is First Tracks Biotherapeutics' Other Financing too high?
First Tracks Biotherapeutics' current Other Financing is $0.00 Mil. Overall, First Tracks Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Other Financing compare to ALT and RGNX?
First Tracks Biotherapeutics' Other Financing of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current Other Financing is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (TRAX) has a current Other Financing of $0.00 Mil. The current Other Financing is $0.00 Mil. First Tracks Biotherapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For First Tracks Biotherapeutics (TRAX), the current Other Financing is $0.00 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges B43:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score

Get the complete analysis for TRAX

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$36.24
Price